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ABSTRACT
We sought, in children after bone marrow transplantation (BMT), (1) to determine the natural history and
incidence of pulmonary complications, (2) to evaluate the diagnostic yield of fiberoptic bronchoscopy and
bronchoalveolar lavage (BAL); and (3) to determine the effect of bronchoscopy with lavage on patient outcome.
The study design was a retrospective review in a tertiary care university hospital of all children undergoing
BMT over a 5-year period. Patients were separated into 2 study groups: children with and without pulmonary
complications. Pulmonary complications were defined as new or persistent pulmonary infiltrates on chest
radiograph or chest computed tomography scan, respiratory symptoms, hypoxemia, or hemoptysis. Three
hundred sixty-three pediatric patients underwent BMT between January 1, 1995, and December 31, 1999.
Ninety patients (25%) developed pulmonary complications and were evaluated with bronchoscopy and BAL.
Patients with pulmonary complications had a higher mortality (65% versus 44%; P < .01). The median
posttransplantation survival for children with pulmonary complications was 258 days, compared with 1572 days
in patients without pulmonary complications. The incidence of pulmonary complications was increased in
patients with allogeneic BMT (P< .01). The time-dependent onset of severe (grade III to IV) graft-versus-host
disease increased the relative risk of pulmonary complications by 2.0 (95% confidence interval, 1.1-3.7; P 
.02). Pulmonary complications increased the time-dependent relative risk of mortality by 3.5 (95% confidence
interval, 2.5-4.8). The diagnostic yield of bronchoscopy with lavage was 46% in patients undergoing BAL.
Diagnostic bronchoscopy did not enhance either 30- or 100-day survival. Pathogen identification did not
decrease mortality (P .45). Pulmonary complications occur in 25% of children undergoing BMT and increase
the risk of death in the first year after BMT. Although pathogen identification does not confer a survival
advantage, rigorous, prospective screening may allow for earlier identification of pathogens and thereby
provide a benefit to this uniquely vulnerable population.
© 2005 American Society for Blood and Marrow Transplantation
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nNTRODUCTION
Since the ﬁrst allogeneic bone marrow transplanta-
ion (BMT) in 1968, BMT has been increasingly used to
reat malignant and nonmalignant hematologic diseases,
mmunodeﬁciencies, metabolic diseases, and autoim-
une diseases in both adults and children [1-3]. Despitec.E. and H.B. contributed equally to this study.
6dvances in the immunobiology of BMT, successful
ransplantation is frequently compromised by infectious
nd noninfectious pulmonary complications [4,5]. Pul-
onary complications have been reported in 40% to
0% of patients after BMT in adult recipients, and 30%
f deaths after BMT are directly attributable to pulmo-
ary complications [6,7]. In children, the incidence and
atural history of pulmonary complications remain in-
ompletely understood.
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Pulmonary Complications in Children after BMT
BPulmonary complications after BMT include
oth infectious and noninfectious disorders (pulmo-
ary edema, idiopathic pneumonia syndrome, dif-
use alveolar hemorrhage, and bronchiolitis obliter-
ns) [7-9]. Pulmonary complications that occur
ithin 100 days of BMT are considered “early,” and
hose after 100 days are considered “late” [6]. The
ype of BMT (autologous versus allogeneic), the
egree of HLA matching, the presence of graft-
ersus-host disease (GVHD), the conditioning reg-
men used, or the recurrence of underlying disease
ould inﬂuence the frequency and severity of pul-
onary complications [10,11].
In pediatric BMT patients with pulmonary com-
lications, diagnostic approaches include chest roent-
enogram and high-resolution computed tomography
CT) [12,13]. Fiberoptic bronchoscopy with bron-
hoalveolar lavage (BAL) is frequently used to evalu-
te for infection in patients with pulmonary compli-
ations after BMT [14-16]. BAL is favored over
ronchial brushing, transbronchial biopsy, and open
ung biopsy because of the diagnostic yield and rela-
ively low rate of complications [17,18]. Standard in-
ications for bronchoscopy with BAL after BMT in-
lude new or persistent pulmonary inﬁltrates on chest
adiograph or chest CT scan, respiratory symptoms
cough, increased work of breathing, hypoxemia, or
emoptysis), or unexplained fever. In adult BMT re-
ipients, speciﬁc diagnoses are obtained from BAL in
pproximately 50% to 80% of patients with pulmo-
ary complications [15,19,20]. BAL is particularly
seful for diagnosis of infections (particularly cyto-
egalovirus [CMV], mycobacterial or other bacterial,
nd fungal infections), can reveal primary or second-
ry malignancy, and is helpful in the diagnosis of
lveolar hemorrhage [21,22]. BAL is of limited valued
n the diagnosis of noninfectious complications. Al-
hough BAL seems to be a useful diagnostic test with
relatively low risk to the patient, whether the results
re predictive of patient outcome or have a direct
ffect on patient management is unknown.
Given the frequency with which bronchoscopy
ith lavage is undertaken as a diagnostic procedure,
his study tested the hypothesis that in pediatric BMT
atients with pulmonary inﬁltrates, bronchoscopy
ith lavage provides diagnostic information that
uides therapy and improves outcome. To rigorously
ddress this hypothesis, data were retrospectively col-
ected from all children undergoing BMT over 5
ears. Evaluation of all children undergoing BMT
ver 5 years allowed determination of the incidence of
ulmonary complications, speciﬁc patient characteris-
ics associated with the development of pulmonary
omplications, the diagnostic yield of bronchoscopy
nd BAL in pediatric BMT patients, and the effect of
ronchoscopy and BAL results on patient outcome
nd overall mortality. s
B&MTETHODS
Clinical and laboratory data were retrieved from
he University of Minnesota Transplant Database,
hich systematically and prospectively collects data on
ll BMT patients at the University of Minnesota
omprehensive Cancer Center. All pediatric patients
ho underwent BMT between January 1, 1995, and
ecember 31, 1999 (n  363), were included. The
atabase provided information regarding demograph-
cs, primary diagnosis, type of BMT, conditioning
egimen, comorbid conditions, and other characteris-
ics (Table 1). Primary diagnoses were divided into 5
roups: leukemia and lymphoma, myelodysplastic syn-
rome and anemias, immunodeﬁciency conditions,
olid tumors, and metabolic diseases. The date of last
ontact or death was recorded to estimate survival.
From the 363 children who underwent BMT dur-
ng the study period, 2 groups of patients were de-
ned: a group with pulmonary complications (n  90)
nd a group without pulmonary complications (n 
73). Children in the pulmonary complications group
eveloped new or persistent pulmonary inﬁltrates on
hest radiograph or chest CT scan, respiratory symp-
oms (cough or increased work of breathing), crackles
n auscultation of the chest, hypoxemia (arterial oxy-
en saturations 90% on room air), or hemoptysis
fter BMT. In 1994, clinicians caring for children
fter BMT had collectively agreed that the develop-
ent of a pulmonary complication, as deﬁned previ-
usly, would result in consultation and ﬁberoptic
ronchoscopy with BAL by the pediatric pulmonol-
gy service. Retrospective patient identiﬁcation was
ccomplished by review of the medical records, in-
luding radiographic information, of all children who
nderwent BMT during the study period. Review of
he medical records of all patients in the data set
onﬁrmed that no patient with pulmonary complica-
ions did not undergo bronchoscopy. For patients who
ad more than 1 BAL, only the results of the ﬁrst BAL
ere used for this analysis.
Cytopathology, bacteriology, mycology, and virol-
gy ﬁndings were analyzed, and each BAL was classiﬁed
s positive or negative on the basis of the yield of patho-
ens or positive cytopathology. A positive BAL result
as deﬁned as a bacterial, fungal, or viral pathogen
solated from culture; a positive fungal stain; a positive
olymerase chain reaction for mycoplasma or chlamydia;
positive silver stain for Pneumocystis jiroveci; or a positive
apid shell vial for CMV. BAL results that yielded only
rganisms likely to be contaminants were considered
egative. Table 2 outlines isolates that were considered
athogens and those that were deemed contaminants.
ronchoscopy and Microbiology Techniques
All patients with pulmonary complications were
een in consultation by the pediatric pulmonary ser-
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5ice. Bronchoscopy was performed either in the pedi-
tric BMT unit or in the operating room. For the
rocedures performed in the BMT unit, the pediatric
ntensive care team provided monitored anesthesia.
elative contraindications to bronchoscopy were co-
gulopathy, severe hypoxia, and hemodynamic insta-
ility. Bronchoscopy was directed to the involved seg-
ent of the lung, as indicated by imaging data.
ormal saline was instilled into the affected segment
n 20-mL aliquots. Lavage was concluded after pro-
urement of 15 mL of lavagate. No child was lavaged
ith more than 6 mL/kg of body weight of normal
aline.
Lavage specimens were arbitrarily divided into 4
able 1. Demographic Characteristics of Children Undergoing Bone M
Factor Pulmonary Complication
otal no. 90
ge, y, median (range) 6.8 (0.2-20.8)
eight, kg, median (range) 20.9 (5-101)
onor type
Autologous 5 (5%)
Matched RD 17 (19%)
Mismatched RD 3 (3%)
Matched URD 33 (37%)
Mismatched URD 32 (35%)
ource of stem cells
Marrow 75 (83%)
PBSC 1 (1%)
Cord blood 14 (16%)
ear of transplantation
1995 18 (20%)
1996 17 (19%)
1997 22 (24%)
1998 17 (19%)
1999 16 (18%)
ex
Male 57 (63%)
Female 33 (37%)
iagnosis
AA 10 (11%)
Hemoglobinopathy 1 (1%)
Immune deficiency 8 (9%)
Storage disease 19 (21%)
ALL 26 (29%)
AML 9 (10%)
CML 3 (3%)
MDS 4 (4%)
NHL/Hodgkin lymphoma 0
Neuroblastoma 1 (1%)
Ovarian 1 (1%)
Other malignancies 8 (9%)
ecipient CMV serostatus
Negative 50 (56%)
Positive 39 (44%)
onditioning
Chemotherapy 
radiation 71 (79%)
Chemotherapy alone 19 (21%)
ollow-up, y, median (range) 4.3 (2.1-6.9)
D indicates related donor; URD, unrelated donor; PBSC, perip
leukemia; AML, acute myelogenous leukemia; CML, chronic
Hodgkin lymphoma; CMV, cytomegalovirus.liquots and sent for cytopathologic evaluation, cell a
8ount, and virology, bacteriology, and fungal studies.
ytopathology was performed with Papanicolaou
tain for cellular atypia and viruses. Grocott methen-
mine silver stain was used for bacteria, fungi, and
neumocystis carinii pneumonia. Microbiology testing
as performed as follows. For bacteriology studies,
avage ﬂuid was centrifuged and Gram-stained, and
nother portion was inoculated into speciﬁc culture
edia. Cultures were examined at 24 and 48 hours.
urther tests and subcultures for identiﬁcation of organ-
sms were performed for positive cultures. Detection of
ycoplasma pneumoniae and Chlamydia pneumoniae was
erformed by using DNA polymerase chain reaction.
pecimens for nocardia testing were Gram-stained,
ransplantation between January 1, 1995, and December 31, 1999
No Pulmonary Complications Total Frequency
273 363
6.7 (0.3-20.4) 6.8 (0.2-20.8)
21 (4.1-123.7) 21 (4.1-123.7)
51 (19%) 56 (15%)
68 (25%) 85 (23%)
6 (2%) 9 (2%)
76 (28%) 109 (30%)
72 (26%) 104 (29%)
211 (77%) 286 (79%)
21 (8%) 22 (6%)
41 (15%) 55 (15%)
57 (21%) 75 (21%)
64 (23%) 81 (22%)
57 (21%) 79 (22%)
54 (20%) 71 (20%)
41 (15%) 57 (16%)
170 (62%) 227 (63%)
103 (38%) 136 (37%)
28 (10%) 38 (10%)
2 (1%) 3 (1%)
14 (5%) 22 (6%)
67 (24%) 86 (24%)
51 (19%) 77 (21%)
41 (15%) 50 (14%)
8 (3%) 11 (3%)
8 (3%) 12 (3%)
2 (1%) 2 (1%)
23 (8%) 24 (7%)
1 (1%) 2 (1%)
28 (10%) 36 (10%)
148 (55%) 198 (55%)
120 (45%) 159 (45%)
196 (72%) 267 (74%)
77 (28%) 96 (26%)
4.3 (1-7.4) 4.3 (1-7.4)
blood stem cells; AA, aplastic anemia; ALL, acute lymphoblastic
genous leukemia; MDS, myelodysplastic syndrome; NHL, non-arrow T
s
heral
myelond, according to appearance, the Kinyoun acid-fast
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Bethod modiﬁed for nocardia was used. Sabouraud
extrose agar, Middlebrook 7H11, and sheep blood
gar were used for cultures. Auramine staining was
sed for detection of acid-fast bacilli. Lowenstein-
ensen slants and liquid BACTEC media were used
or culture testing. More selective media were used for
dentifying species on the initial culture growth. Spec-
mens for fungal testing were centrifuged, and the
ediment was stained with KOH; another part was
noculated into speciﬁc media (sheep blood, inhibitory
old, blood agar). Routine fungal cultures were incu-
ated for 4 weeks before negative results were re-
orted. The culture results were evaluated semiquan-
itatively. All BAL specimens were tested for CMV
ith rapid shell vial assays (Meriﬂuor CMV, Meridian
iagnostics, Inc., Cincinnati, OH), which allows de-
ection of CMV in 16 hours. The other part of the
pecimen was processed and inoculated into 3 cell
ultures (SF, A549, and Hep-2). Positive results were
eported in 1 to 3 weeks.
tatistical Methods
The cumulative incidence of pulmonary compli-
ations over time was calculated by treating death
rom other causes as a competing risk [23]. Compar-
sons of the incidence of pulmonary complications and
urvival after the procedure by various factors (Tables 3
nd 4) were performed by the log-rank test. Among
atients who underwent bronchoscopy, the survival
ate was estimated by the Kaplan-Meier method [24].
urvival by time-dependent onset of BAL and BAL by
ime-dependent onset of GVHD were calculated by a
odiﬁed Kaplan-Meier technique and Cox regression
25]. Cox regression was also used to determine the
able 2. Survival
Factor n Died
verall 90 46
ungal isolate
No 72 36
Yes 13 8
iagnostic BAL—microbiology
No pathogen 50 23
Pathogen 40 23
iagnostic BAL—cytopathology
No pathogen 73 36
Pathogen 12 7
iagnostic BAL—both
No pathogen 48 22
Pathogen 42 24
ear of transplantation
1995 18 15
1996 17 7
1997 22 10
1998 17 6
1999 16 8
I indicates conﬁdence interval; BAL, bronchoalveolar lavage.ndependent effect of factors on the risk of pulmonary i
B&MTomplications. All variables were tested for propor-
ional hazards before inclusion in the model. A P value
.05 was considered signiﬁcant.
ESULTS
Three hundred sixty-three patients between the
ges of 2 months and 21 years underwent BMT at the
niversity of Minnesota between January 1, 1995, and
ecember 31, 1999. Ninety patients (25%) developed
ulmonary inﬁltrates or symptoms that resulted in
iagnostic bronchoscopy with BAL during the same
ime period (BAL group), whereas 273 (75%) did not
evelop pulmonary complications (non-BAL group).
emographic Factors
Age, weight, and other demographic factors are
ummarized in Table 1. The median age of the pa-
ients at the time of BMT was 6.8 years (range, 2
onths to 21 years). By age group, no differences
ere found in the frequency of pulmonary complica-
ions (P  .50). More males than females underwent
MT (63% versus 37%, respectively).
urvival
For all pediatric BMT patients, the median sur-
ival was 1063 days. Three-year mortality was 49%.
osttransplantation mortality in the group with pul-
onary complications was 64%, compared with 45%
n the group without pulmonary complications. Me-
ian survival in the group with pulmonary complica-
ions was 258 days after transplantation, as opposed to
572 days in patients without pulmonary pathology, as
30 d
(95% CI)
100 d
(95% CI) P Value
63% (53%-73%) 49% (39%-59%)
67% (56%-78%) 50% (39%-61%) .17
46% (19%-73%) 38% (12%-64%)
68% (55%-81%) 54% (40%-68%) .28
58% (43%-73%) 43% (28%-58%)
67% (56%-78%) 51% (40%-62%) .30
50% (22%-78%) 42% (14%-70%)
69% (56%-82%) 54% (40%-68%) .25
57% (42%-72%) 43% (28%-58%)
44% (21%-67%) 17% (0%-34%) .03
59% (36%-82%) 59% (36%-82%)
68% (48%-88%) 55% (34%-76%)
71% (49%-100%) 65% (42%-88%)
75% (54%-96%) 50% (25%-75%)llustrated by the Kaplan-Meier plot in Figure 1.
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6hirty-three percent of nonsurvivors developed pul-
onary complications, in contrast to 18% in the sur-
ivor group. Time-dependent analysis of survival by
nset of pulmonary complications revealed a relative
isk of mortality of 3.5 (95% conﬁdence interval [CI],
.5-4.8; P  .01). The identiﬁcation of a pathogen by
AL (including fungal isolates) was not associated
ith increased mortality, as demonstrated in Table 4
P  .25) and Figure 2.
MV Status
CMV seropositivity was not associated with an
ncreased incidence of pulmonary complications. The
-year incidence of pulmonary complications was
1% (95% CI, 15%-27%) in the CMV-positive group
nd 24% (95% CI, 18%-30%) in the CMV-negative
roup. At 3 years, the incidence of pulmonary com-
lications was 25% in both groups (P  .92).
raft-versus-Host Disease
More patients with severe GVHD developed pul-
onary complications than patients without severe
VHD. The relative risk of developing pulmonary
omplications by time-dependent onset of severe
grade III or IV) GVHD was 2.0 (95% CI, 1.1-3.7;
able 3. Overall Incidence and Subgroup Analysis of Pulmonary Comp
Factor n
verall 363
ge at transplantation (y)
0-1 67
2-10 178
>11 118
onor type
Autologous 56
RD 94
URD 213
iagnosis
AA/MDS 53
Immune deficiency 22
Storage disease 86
Leukemia/lymphoma 148
Solid tumor 54
MV serostatus
Negative 198
Positive 159
onditioning
Radiation 267
No radiation 96
rade III-IV acute GVHD
No 269
Yes 38
ear of transplantation
1995 75
1996 81
1997 79
1998 71
1999 57
I indicates conﬁdence interval; BAL, bronchoalveolar lavage; R
myelodysplastic syndrome; CMV, cytomegalovirus; GVHD, gr .02). m
0onditioning Regimen
Radiation as part of the conditioning regimen had
o effect on the 1- or 3-year incidence of pulmonary
omplications. Children who received radiation had a
-year incidence of 25% (95% CI, 20%-30%), as
pposed to 18% (95% CI, 10%-26%) in those who
id not receive radiation. The results were similar at 3
ears (P  .21).
onor Type
The distribution of patients with pulmonary com-
lications relative to BMT donor type is summarized
n Table 3. Both related donor and unrelated donor
llogeneic BMT patients were more likely to develop
ulmonary complications than patients who had au-
ologous transplantations (P  .01).
rimary Diagnosis
The distribution of pulmonary complications by
iagnostic category is shown in Table 3. No difference
as found in the frequency of pulmonary complica-
ions between diagnostic groups, with the exception of
hose undergoing BMT for solid tumors. Fewer pa-
ients (9%) in the solid-tumor group developed pul-
in Children after Bone Marrow Transplantation
1-y Incidence (95% CI) P Value
23% (19%-27%)
28% (17%-39%) .50
21% (15%-27%)
22% (15%-29%)
7% (1%-13%) <.01
19% (11%-27%)
29% (23%-35%)
26% (14%-38%) .04
36% (16%-56%)
22% (13%-31%)
26% (19%-33%)
7% (0%-14%)
24% (18%-30%) .92
21% (15%-27%)
25% (20%-30%) .21
18% (10%-26%)
26% (21%-31%) .42
26% (12%-40%)
21% (12%-30%) .75
19% (11%-27%)
25% (15%-35%)
23% (13%-33%)
28% (16%-40%)
ated donor; URD, unrelated donor; AA, aplastic anemia; MDS,
us-host disease.lications
BAL
90
19
40
31
5
20
65
15
8
19
43
5
50
39
71
19
72
13
18
17
22
17
16
D, relonary complications (P  .04), but this effect was
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Pulmonary Complications in Children after BMT
Bonfounded by the fact that most of these patients had
utologous transplantations. With multiple regression
nalysis, the effect disappeared.
ultiple Regression
Cox regression showed that the only factors inde-
endently associated with the development of pulmo-
ary complications were grade III or IVGVHD (relative
isk, 2.0; 95%CI, 1.1-3.7) and allogeneic transplantation
relative risk, 3.2; 95% CI, 1.3-7.8).
echanical Ventilation
Eighty-six (96%) patients undergoing bronchos-
opy for pulmonary complications were mechanically
entilated at some point during their hospital course.
ortality among those undergoing mechanical venti-
ation was 65%.
iagnostic Yield
The 90 BAL results reviewed included 90 micro-
iology examinations and 85 cytopathology examina-
ions. Pathogens were identiﬁed in 46% of patients
ho underwent BAL. Microbiology yielded positive
esults in 45% of patients, in contrast to cytopathol-
gy, which yielded positive results in only 15% of
atients. There was only 1 instance in which cytopa-
hology revealed a pathogen with negative microbiol-
gy results. Cytopathology did not reveal malignancy
n any circumstance, but it was more likely to reveal
ungal elements. Pathogens were identiﬁed in 42% of
urvivors and 50% of nonsurvivors. As summarized in
able 4, no differences were found in 30- or 100-day
urvival for patients with a positive fungal isolate (P 
able 4. Association between Diagnostic Bronchoscopy and Patient Surv
Factor n Died
verall 90 46
ungal isolate
No 72 36
Yes 13 8
iagnostic BAL—microbiology
No pathogen 50 23
Pathogen 40 23
iagnostic BAL—cytopathology
No pathogen 73 36
Pathogen 12 7
iagnostic BAL—both
No pathogen 48 22
Pathogen 42 24
ear of transplantation
1995 18 15
1996 17 7
1997 22 10
1998 17 6
1999 16 8
I indicates conﬁdence interval; BAL, bronchoalveolar lavage.17), positive cultures (P  .28), positive cytopathol- g
B&MTgy (P  .25), or overall positive BAL (P  .25). The
aplan-Meier plot in Figure 2 demonstrates no dif-
erence in survival between groups with positive and
egative BAL results.
ISCUSSION
The data presented in this series support the con-
ept that pulmonary complications after BMT are a
oor prognostic event associated with a signiﬁcantly
ncreased risk for mortality. In this series, 25% of
atients developed pulmonary complications. Of these
atients, 96% were intubated and mechanically ven-
ilated at some point during their hospital course.
ortality in the group with pulmonary complications
as 64%, as compared with 45% in the patients with-
ut pulmonary disease, representing a relative risk of
eath of 3.5 (P  .01). Despite the relatively favorable
iagnostic yield of bronchoscopy with lavage (46%),
0- or 100-day survival did not differ between patients
ith positive BAL results and those with no pathogen
solated (P  .25). These ﬁndings held true irrespec-
ive of the type of pathogen identiﬁed (fungal culture,
 .17; bacterial culture, P .28) or the timeliness of
iagnosis (cytopathology, P  .3). Surprisingly, there
as no correlation between CMV serostatus, acute
VHD, irradiation, and the incidence of pulmo-
ary complications. Consistent with previous re-
orts, these data support the notion that autologous
MT is associated with a lower risk of pulmonary
omplications [17,26].
The striking difference in mortality between pa-
ients with and without pulmonary complications sug-
30 d
(95% CI)
100 d
(95% CI) P Value
63% (53%-73%) 49% (39%-59%)
67% (56%-78%) 50% (39%-61%) .17
46% (19%-73%) 38% (12%-64%)
68% (55%-81%) 54% (40%-68%) .28
58% (43%-73%) 43% (28%-58%)
67% (56%-78%) 51% (40%-62%) .30
50% (22%-78%) 42% (14%-70%)
69% (56%-82%) 54% (40%-68%) .25
57% (42%-72%) 43% (28%-58%)
44% (21%-67%) 17% (0%-34%) .03
59% (36%-82%) 59% (36%-82%)
68% (48%-88%) 55% (34%-76%)
71% (49%-100%) 65% (42%-88%)
75% (54%-96%) 50% (25%-75%)ivalests that our current approach toward the diagnosis
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6nd treatment of these conditions is inadequate. One
nterpretation of these ﬁndings is that standard signs
nd symptoms of pulmonary disease may become ev-
dent only after irreversible disease progression has
ccurred in this uniquely vulnerable patient popula-
ion.
This study is one of the largest to date evaluating
ulmonary complications in a heterogeneous group of
ediatric BMT recipients. The size of the population
tudied provides insight into the natural history of
ulmonary complications in this population and iden-
iﬁes factors associated with the development of pul-
onary complications. Although bronchoscopy with
avage is commonly used, even a diagnostic procedure
oes not improve outcome in the immunosuppressed
hild with pulmonary symptoms. This study is the ﬁrst
n a pediatric population to link the yield of diagnostic
ronchoscopy with patient outcome.
There were no differences in the incidence of
ulmonary complications by age category (P  .5).
he observation that pulmonary complications were
venly distributed across age categories indicates that
nfants are not at greater risk for the development of
ulmonary complications. Consistent with previous
eports, this report suggests that children undergoing
llogeneic BMT are at a greater risk for the develop-
ent of pulmonary complications than patients re-
eiving autologous transplants (P  .01) [17,26]. Sim-
larly, those undergoing transplantation for solid
umors were less likely to develop pulmonary compli-
ations (P  .04), presumably because these patients
ndergo autologous BMT. No difference in the inci-
ence of pulmonary complications was found between
ther diagnostic categories.
The relative risk of developing pulmonary com-
igure 1. Kaplan-Meier plot of survival of children after bone
arrow transplantation. Survival in patients without pulmonary
omplications (solid line) is compared with survival in patients
ithout pulmonary complications (dashed line). Patients without
ulmonary complications are more likely to survive than patients
ith pulmonary complications (P.001).lications by time-dependent onset of grade III or IV p
2VHD was 2.0 (95% CI, 1.1-3.7; P  .02) [26]. The
nclusion of total body irradiation as part of the con-
itioning regimen was not associated with an in-
reased incidence of pulmonary complications in this
eries (P .21), despite data demonstrating a relation-
hip between radiation and lung injury [27,28]. Exper-
mental models suggest that radiation in concert with
hemotherapy may lead to idiopathic pneumonia syn-
rome and lung injury [29-31]. It is interesting to note
hat CMV-seropositive patients did not have a higher
ncidence of pulmonary complications; this suggests
hat antiviral therapy is effective in preventing invasive
ung disease. Although the retrospective study design
recludes deﬁnitive statements regarding causality,
his study suggests that the development of pulmonary
omplications after BMT is a complex, multifactorial
rocess that involves more than 1 predisposing con-
ition or risk factor.
The observation that virtually all of the patients
ith pulmonary complications in this trial were intu-
ated and mechanically ventilated during the course of
ospitalization supports the notion that pulmonary
omplications after BMT are associated with high
orbidity and mortality. Although 65% of the pa-
ients treated with mechanical ventilation did not sur-
ive the hospitalization, many did survive. Given the
urvival of more than one third of all patients who
ere treated with intubation and mechanical ventila-
ion after BMT, these data provide justiﬁcation for
igorously supporting children with respiratory failure
fter BMT. The observation that virtually all patients
ith pulmonary complications in this trial underwent
echanical ventilation may imply that pulmonary
omplications are a sentinel event in the development
f multisystem organ failure. One of the limitations of
his data set is our inability to determine whether
igure 2. Kaplan-Meier plot of survival of children with pulmonary
omplications after bone marrow transplantation. Children who
nderwent a diagnostic bronchoscopy (dashed line) had no survival
dvantage compared with children who underwent bronchoscopy
hat did not yield a diagnosis (solid line).ulmonary complications led to multiorgan system
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Bailure or whether multiorgan system failure entailed
ulmonary complications. Notwithstanding this limi-
ation, these data justify the statement that most chil-
ren who develop pulmonary complications in the
ost-BMT period will require mechanical ventilation
nd that a signiﬁcant percentage of mechanically ven-
ilated children will survive the hospitalization.
This report contrasts with the ﬁndings of von Eiff
t al. [32], wherein diagnostic bronchoscopy conferred
nhanced outcome in adults with hematologic malig-
ancies and varying degrees of immunosuppression.
oreover, survival was improved by the performance
f diagnostic bronchoscopy, thus indicating that ther-
py was altered to address pathogens identiﬁed by
ronchoscopy, whereas patients with nondiagnostic
AL results had less favorable outcomes. Consistent
ith this report, 2 studies in adult BMT recipients
ave failed to show a survival beneﬁt [17,33]. How-
ver, 2 relatively recent publications suggest that de-
ermination of the cytokine proﬁle of cells isolated
rom the lavage ﬂuid may provide important diagnos-
ic and prognostic information [34,35]. Despite the
avorable diagnostic yield from BAL in our series,
iagnostic BAL was not associated with an improved
utcome. As illustrated in Figure 2, a diagnostic BAL
ad no effect on survival. One interpretation of these
ndings is that by the time pathology is evident with
he standard diagnostic approach, it may be too late to
uccessfully intervene. As Hilbert et al. [36] reported,
arly intervention with noninvasive positive pressure
entilation in immunocompromised patients de-
reased the incidence of endotracheal intubation and
mproved survival to hospital discharge. Perhaps more
ffective and sensitive diagnostic strategies that allow
or earlier recognition of pulmonary disease and,
herefore, more timely initiation of therapeutic inter-
entions might also confer a survival advantage.
The retrospective study design precludes causal
ttribution. Although our diagnostic and therapeutic
pproach to children with pulmonary complications
fter BMT is highly standardized, it is impossible to
ompletely account for differences in the management
f the patients under study. This may explain the
ivergence in 30- and 100- day survival in patients
ho underwent transplantation in 1995 relative to
hildren who underwent BMT more recently. In the
bsence of a formal prospective screening protocol for
ulmonary complications, it is possible that patients
ith mild pulmonary disease were not included in this
tudy. However, given the systematic review of all
ediatric BMT patients during the study period, as
ell as the natural history of pulmonary complications
fter BMT, this number is likely to be quite small.
Despite advances in the diagnosis and therapy of
ulmonary complications in patients after BMT, mor-
idity and mortality remain high. Patients with pul-
onary complications after BMT are much more
B&MTikely to die than patients without pulmonary involve-
ent. Fiberoptic bronchoscopy with BAL effectively
dentiﬁed infectious pathogens but did not enhance
urvival rate. Thus, it seems prudent to search for
ore sensitive indicators of lung disease so that lung
athology can be identiﬁed earlier and treatment ini-
iated in a more timely fashion than is currently stan-
ard. These data may justify screening for potential
ulmonary pathogens before transplantation.
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